Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Apurinic/apyrimidinic endonuclease 1 (APE1/Ref‐1) overexpression is an independent prognostic marker in prostate cancer without TMPRSS2:ERG fusion

3 May 2017

Abstract excerpt

Polymorphisms of the base excision repair gene APE1 may be associated with an increased risk for developing prostate cancer. In other cancer types, altered APE1 protein expression is a candidate prognostic marker. Using immunohistochemistry, we thus analyzed APE1 expression in 9763 prostate cancers in a tissue microarray (TMA) with attached clinical and molecular data. The comparison with normal prostate tissue...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy
Share to Prostate Cancer Treatment and Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28467610
DOI: 10.1002/mc.22670

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Apurinic/apyrimidinic endonuclease 1 (APE1/Ref‐1) overexpression is an independent prognostic marker in prostate cancer without TMPRSS2:ERG fusionPMID 28467610Read ↗

Increased ERCC1 expression is linked to chromosomal aberrations and adverse tumor biology in prostate cancerSemantic proximity Read ↗

Systematic analysis reveals molecular characteristics of ERG-negative prostate cancer.Semantic proximity Read ↗

Association of Prostate Cancer Risk Variants with TMPRSS2:ERG Status: Evidence for Distinct Molecular Subtypes.Semantic proximity Read ↗

Epigenomic profiling of prostate cancer identifies differentially methylated genes in TMPRSS2:ERG fusion-positive versus fusion-negative tumorsSemantic proximity Read ↗

ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratificationSemantic proximity Read ↗

Characterization of 1577 primary prostate cancers reveals novel biological and clinicopathologic insights into molecular subtypes.Semantic proximity Read ↗

ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor.Semantic proximity Read ↗

Clinical Applications of Novel ERG Immunohistochemistry in Prostate Cancer Diagnosis and ManagementSemantic proximity Read ↗

Up regulation and nuclear translocation of Y-box binding protein 1 (YB-1) is linked to poor prognosis in ERG-negative prostate cancerSemantic proximity Read ↗

Oncogenic activation of <i>ERG:</i> A predominant mechanism in prostate cancerSemantic proximity Read ↗

Comprehensive analysis of oncogenic signatures and consequent repurposed drugs in TMPRSS2:ERG fusion‐positive prostate cancerSemantic proximity Read ↗

High levels of 5-hydroxymethylcytosine (5hmC) is an adverse predictor of biochemical recurrence after prostatectomy in ERG-negative prostate cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.